Viatris Inc

Research Viatris Inc (VTRS) on Bullrun: market cap USD 19.32B, dividend yield 2.8%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 19.32B; dividend yield is 2.8%.

Peer valuation comparison

Latest dividend yield is 2.84% versus a Healthcare sector median of 2.11% (34.6% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 14.25B-USD 3.51BUSD 1.94B35.2%-3USD 1.32BUSD 14.41BUSD 14.71B
FY2024USD 14.69B-USD 634.20MUSD 1.98B38.3%-0.53USD 734.80MUSD 14.04BUSD 18.64B
FY2023USD 15.39BUSD 54.70MUSD 2.52B41.8%0.05USD 991.90MUSD 18.12BUSD 20.47B
FY2022USD 16.22BUSD 2.08BUSD 2.59B40.1%1.71USD 1.26BUSD 19.27BUSD 21.07B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 19.32Bn/a2.9%0.48
20252025-12-31USD 14.33Bn/a3.9%0.48
20242024-12-31USD 14.86Bn/a3.9%0.48
20232023-12-29USD 12.99B7.24.4%0.48
20222022-12-30USD 13.50B16.94.3%0.48
20212021-12-31USD 16.36Bn/a2.4%0.33

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0.48 USD, yield 2.8%.

YearDividends/share
FY20250.48 USD
FY20240.48 USD
FY20230.48 USD
FY20220.48 USD

About Viatris Inc

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Viatris Inc's market cap?

Viatris Inc's market capitalization is USD 19.32B.

Does Viatris Inc pay a dividend?

Viatris Inc has a dividend yield of 2.8%.

What does Viatris Inc do?

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars.